Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 124,363
- 试验地点
- 1
- 主要终点
- The overall composite of 11 performance measures for ACS care
研究概览
简要总结
To develop and implement quality improvement programs for the treatment of acute coronary syndrome (ACS) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of acute coronary syndrome.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized patients with discharge diagnosis as acute coronary syndrome (including STEMI, NSTEMI and UAP) in 150 tertiary and 100 secondary hospitals.
排除标准
- 未提供
结局指标
主要结局
The overall composite of 11 performance measures for ACS care
时间窗: Duration of hospital stay, an expected average of 1 week
Performance measures for ACS care including: 1. Proportion of patients received aspirin at arrival 2. Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) 3. Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) 4. Proportion of patients received reperfusion therapy (STEMI) 5. Proportion of patients with aspirin prescribed at discharge 6. Proportion of patients with clopidogrel or other P2Y12 inhibitors prescribed at discharge 7. Proportion of patients with beta-blocker prescribed at discharge 8. Proportion of patients with statin prescribed at discharge 9. Proportion of patients received evaluation of left ventricular systolic function 10. Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge 11. Proportion of patients received smoking cessation advice/ counseling
次要结局
未报告次要终点
研究者
Dong ZHAO
Principal Investigator
Beijing Institute of Heart, Lung and Blood Vessel Diseases
